Table 2.
Clinical trials of adenoviral vector‐based COVID‐19 vaccines
| Vaccine name | Company/Sponsor | Vector | Antigen | Route | Phase | No. of participants | Protection efficacy | NCT |
|---|---|---|---|---|---|---|---|---|
| Ad5‐nCoV | CanSino Biologicals | HAd5 | SARS‐CoV‐2 S protein | i.m. | I | 108 | 65% | NCT04313127 |
| II | 508 | NCT04341389 | ||||||
| III | 40 000 | NCT04526990 | ||||||
| Ad26.COV2.S | Johnson & Johnson/Janssen | HAd26 | SARS‐CoV‐2 S protein | i.m. | I | 250 | 85% | NCT04509947 |
| II | 1085 | NCT04436276 | ||||||
| III | 44 325 | NCT04505722 | ||||||
| Gam‐COVID‐Vac/Sputnik‐V | Gamaleya National Institute for Research in Epidemiology and Microbiology | HAd5 and HAd26 | SARS‐CoV‐2 S protein | i.m. | I | 38 | 91.6% | NCT04436471 |
| II | 1600 | NCT04640233 | ||||||
| III | 33 758 | NCT04530396 | ||||||
| AZD1222 nCoV‐19 | University of Oxford/AstraZeneca | ChAd‐Y25 | SARS‐CoV‐2 S protein | i.m. | I/II | 1090 | 82% | NCT04324606 |
| III | 32 459 | NCT04516746 |
ChAd, chimpanzee adenovirus; HAd5, human adenovirus type 5; HAd26, human adenovirus type 26; i.m., intramuscular; NCT, national clinical trial; S, spike.